You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
771 A phase 1 study to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intratumoral CLN-617 (IL2/IL12 fusion protein) combined with pembrolizumab in patients with advanced solid tumors
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address